Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)
PFIZER CANADA ULC
J01CR05
PIPERACILLIN AND BETA-LACTAMASE INHIBITOR
3G; 375MG
POWDER FOR SOLUTION
PIPERACILLIN (PIPERACILLIN SODIUM) 3G; TAZOBACTAM (TAZOBACTAM SODIUM) 375MG
INTRAVENOUS
17.36ML
Prescription
EXTENDED-SPECTRUM PENICILLINS
Active ingredient group (AIG) number: 0225919003; AHFS:
CANCELLED POST MARKET
2015-02-26
_ _ _TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_ _ _ _Page 1 of 43 _ PRODUCT MONOGRAPH PR TAZOCIN ® Piperacillin and Tazobactam powder for injection 2.0g/0.25g, 3g/0.375g, 4.0g/0.5g per vial (as piperacillin sodium and tazobactam sodium) Lyophilized Powder for Injection Antibiotic/ß-lactamase Inhibitor Pfizer Canada Inc 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Revision: April 8, 2014 Submission Control No: 171562 ® TM Wyeth Holdings Corporation, Pfizer Canada Inc., Licensee _ _ _TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_ _ _ _Page 2 of 43 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ............................................................20 STORAGE AND STABILITY ..........................................................................................23 SPECIAL HANDLING INSTRUCTIONS .......................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................23 PART II: SCIENTIFIC INFORMATION .... Đọc toàn bộ tài liệu